220 related articles for article (PubMed ID: 31075200)
21. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M
J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127
[TBL] [Abstract][Full Text] [Related]
22. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
23. Development of a Small Molecule Tubulysin B Conjugate for Treatment of Carbonic Anhydrase IX Receptor Expressing Cancers.
Marks IS; Gardeen SS; Kurdziel SJ; Nicolaou ST; Woods JE; Kularatne SA; Low PS
Mol Pharm; 2018 Jun; 15(6):2289-2296. PubMed ID: 29715036
[TBL] [Abstract][Full Text] [Related]
24. In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen.
Li Y; Tian Z; Rizvi SM; Bander NH; Allen BJ
Prostate Cancer Prostatic Dis; 2002; 5(1):36-46. PubMed ID: 15195129
[TBL] [Abstract][Full Text] [Related]
25. Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts.
DiPippo VA; Olson WC; Nguyen HM; Brown LG; Vessella RL; Corey E
Prostate; 2015 Feb; 75(3):303-13. PubMed ID: 25327986
[TBL] [Abstract][Full Text] [Related]
26. Preclinical Evaluation of
Cardinale J; Schäfer M; Benešová M; Bauder-Wüst U; Leotta K; Eder M; Neels OC; Haberkorn U; Giesel FL; Kopka K
J Nucl Med; 2017 Mar; 58(3):425-431. PubMed ID: 27789722
[TBL] [Abstract][Full Text] [Related]
27. Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand.
Kularatne SA; Wang K; Santhapuram HK; Low PS
Mol Pharm; 2009; 6(3):780-9. PubMed ID: 19361233
[TBL] [Abstract][Full Text] [Related]
28. Development of 5D3-DM1: A Novel Anti-Prostate-Specific Membrane Antigen Antibody-Drug Conjugate for PSMA-Positive Prostate Cancer Therapy.
Huang CT; Guo X; Bařinka C; Lupold SE; Pomper MG; Gabrielson K; Raman V; Artemov D; Hapuarachchige S
Mol Pharm; 2020 Sep; 17(9):3392-3402. PubMed ID: 32803984
[TBL] [Abstract][Full Text] [Related]
29. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.
Elsässer-Beile U; Wolf P; Gierschner D; Bühler P; Schultze-Seemann W; Wetterauer U
Prostate; 2006 Sep; 66(13):1359-70. PubMed ID: 16894535
[TBL] [Abstract][Full Text] [Related]
30. Near-Infrared Photoimmunotherapy Targeting Prostate Cancer with Prostate-Specific Membrane Antigen (PSMA) Antibody.
Nagaya T; Nakamura Y; Okuyama S; Ogata F; Maruoka Y; Choyke PL; Kobayashi H
Mol Cancer Res; 2017 Sep; 15(9):1153-1162. PubMed ID: 28588059
[TBL] [Abstract][Full Text] [Related]
31. A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer.
Chatalic KL; Veldhoven-Zweistra J; Bolkestein M; Hoeben S; Koning GA; Boerman OC; de Jong M; van Weerden WM
J Nucl Med; 2015 Jul; 56(7):1094-9. PubMed ID: 25977460
[TBL] [Abstract][Full Text] [Related]
32. Quantitative [Fe]MRI determination of the dynamics of PSMA-targeted SPIONs discriminates among prostate tumor xenografts based on their PSMA expression.
Sillerud LO
J Magn Reson Imaging; 2018 Aug; 48(2):469-481. PubMed ID: 29331081
[TBL] [Abstract][Full Text] [Related]
33.
Nonnekens J; Chatalic KL; Molkenboer-Kuenen JD; Beerens CE; Bruchertseifer F; Morgenstern A; Veldhoven-Zweistra J; Schottelius M; Wester HJ; van Gent DC; van Weerden WM; Boerman OC; de Jong M; Heskamp S
Cancer Biother Radiopharm; 2017 Mar; 32(2):67-73. PubMed ID: 28301262
[TBL] [Abstract][Full Text] [Related]
34. Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer.
Petrylak DP; Kantoff P; Vogelzang NJ; Mega A; Fleming MT; Stephenson JJ; Frank R; Shore ND; Dreicer R; McClay EF; Berry WR; Agarwal M; DiPippo VA; Rotshteyn Y; Stambler N; Olson WC; Morris SA; Israel RJ
Prostate; 2019 May; 79(6):604-613. PubMed ID: 30663074
[TBL] [Abstract][Full Text] [Related]
35. Pre-clinical evaluation of EC1456, a folate-tubulysin anti-cancer therapeutic.
Reddy JA; Dorton R; Bloomfield A; Nelson M; Dircksen C; Vetzel M; Kleindl P; Santhapuram H; Vlahov IR; Leamon CP
Sci Rep; 2018 Jun; 8(1):8943. PubMed ID: 29895863
[TBL] [Abstract][Full Text] [Related]
36. Targeted Tubulysin B Hydrazide Conjugate for the Treatment of Luteinizing Hormone-Releasing Hormone Receptor-Positive Cancers.
Roy J; Kaake M; Srinivasarao M; Low PS
Bioconjug Chem; 2018 Jul; 29(7):2208-2214. PubMed ID: 29851465
[TBL] [Abstract][Full Text] [Related]
37. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.
Weineisen M; Schottelius M; Simecek J; Baum RP; Yildiz A; Beykan S; Kulkarni HR; Lassmann M; Klette I; Eiber M; Schwaiger M; Wester HJ
J Nucl Med; 2015 Aug; 56(8):1169-76. PubMed ID: 26089548
[TBL] [Abstract][Full Text] [Related]
38. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and Biological Evaluation of PSMA Ligands with Aromatic Residues and Fluorescent Conjugates Based on Them.
Machulkin AE; Shafikov RR; Uspenskaya AA; Petrov SA; Ber AP; Skvortsov DA; Nimenko EA; Zyk NU; Smirnova GB; Pokrovsky VS; Abakumov MA; Saltykova IV; Akhmirov RT; Garanina AS; Polshakov VI; Saveliev OY; Ivanenkov YA; Aladinskaya AV; Finko AV; Yamansarov EU; Krasnovskaya OO; Erofeev AS; Gorelkin PV; Dontsova OA; Beloglazkina EK; Zyk NV; Khazanova ES; Majouga AG
J Med Chem; 2021 Apr; 64(8):4532-4552. PubMed ID: 33822606
[TBL] [Abstract][Full Text] [Related]
40. Prostate-specific membrane antigen targeted protein contrast agents for molecular imaging of prostate cancer by MRI.
Pu F; Salarian M; Xue S; Qiao J; Feng J; Tan S; Patel A; Li X; Mamouni K; Hekmatyar K; Zou J; Wu D; Yang JJ
Nanoscale; 2016 Jul; 8(25):12668-82. PubMed ID: 26961235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]